These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12462152)

  • 1. Defining HIV-1 protease substrate selectivity.
    Beck ZQ; Morris GM; Elder JH
    Curr Drug Targets Infect Disord; 2002 Mar; 2(1):37-50. PubMed ID: 12462152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent developments of peptidomimetic HIV-1 protease inhibitors.
    Qiu X; Liu ZP
    Curr Med Chem; 2011; 18(29):4513-37. PubMed ID: 21864279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of efficiently cleaved substrates for HIV-1 protease using a phage display library and use in inhibitor development.
    Beck ZQ; Hervio L; Dawson PE; Elder JH; Madison EL
    Virology; 2000 Sep; 274(2):391-401. PubMed ID: 10964781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
    Lefebvre E; Schiffer CA
    AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of symmetry-based, peptidomimetic inhibitors of human immunodeficiency virus protease.
    Kempf DJ
    Methods Enzymol; 1994; 241():334-54. PubMed ID: 7854187
    [No Abstract]   [Full Text] [Related]  

  • 6. Using Hierarchical Virtual Screening To Combat Drug Resistance of the HIV-1 Protease.
    Li N; Ainsworth RI; Ding B; Hou T; Wang W
    J Chem Inf Model; 2015 Jul; 55(7):1400-12. PubMed ID: 25993532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
    Nijhuis M; van Maarseveen NM; Lastere S; Schipper P; Coakley E; Glass B; Rovenska M; de Jong D; Chappey C; Goedegebuure IW; Heilek-Snyder G; Dulude D; Cammack N; Brakier-Gingras L; Konvalinka J; Parkin N; Kräusslich HG; Brun-Vezinet F; Boucher CA
    PLoS Med; 2007 Jan; 4(1):e36. PubMed ID: 17227139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crucial amides for dimerization inhibitors of HIV-1 protease.
    Bowman MJ; Chmielewski J
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1395-8. PubMed ID: 15006369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of HIV-1 protease.
    Meek TD
    J Enzyme Inhib; 1992; 6(1):65-98. PubMed ID: 1285304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease.
    Chellappan S; Kairys V; Fernandes MX; Schiffer C; Gilson MK
    Proteins; 2007 Aug; 68(2):561-7. PubMed ID: 17474129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in automated docking applied to human immunodeficiency virus type 1 protease.
    Miller MD; Sheridan RP; Kearsley SK; Underwood DJ
    Methods Enzymol; 1994; 241():354-70. PubMed ID: 7854188
    [No Abstract]   [Full Text] [Related]  

  • 12. Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate.
    Kolli M; Lastere S; Schiffer CA
    Virology; 2006 Apr; 347(2):405-9. PubMed ID: 16430939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural insights into the mechanisms of drug resistance in HIV-1 protease NL4-3.
    Heaslet H; Kutilek V; Morris GM; Lin YC; Elder JH; Torbett BE; Stout CD
    J Mol Biol; 2006 Mar; 356(4):967-81. PubMed ID: 16403521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance.
    Nalam MN; Ali A; Altman MD; Reddy GS; Chellappan S; Kairys V; Ozen A; Cao H; Gilson MK; Tidor B; Rana TM; Schiffer CA
    J Virol; 2010 May; 84(10):5368-78. PubMed ID: 20237088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural implications of drug-resistant mutants of HIV-1 protease: high-resolution crystal structures of the mutant protease/substrate analogue complexes.
    Mahalingam B; Louis JM; Hung J; Harrison RW; Weber IT
    Proteins; 2001 Jun; 43(4):455-64. PubMed ID: 11340661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Domain flexibility in retroviral proteases: structural implications for drug resistant mutations.
    Rose RB; Craik CS; Stroud RM
    Biochemistry; 1998 Feb; 37(8):2607-21. PubMed ID: 9485411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic profiling of substrate binding response to multidrug-resistant mutations in HIV-1 protease: Implication for combating drug resistance.
    Lv Y; Li J; Fang J; Jiao X; Yan L; Shan B
    J Mol Graph Model; 2017 Jun; 74():83-88. PubMed ID: 28371730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligand modifications to reduce the relative resistance of multi-drug resistant HIV-1 protease.
    Dewdney TG; Wang Y; Liu Z; Sharma SK; Reiter SJ; Brunzelle JS; Kovari IA; Woster PM; Kovari LC
    Bioorg Med Chem; 2013 Dec; 21(23):7430-4. PubMed ID: 24128815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of HIV-1 protease: the rigidity perspective.
    Heal JW; Jimenez-Roldan JE; Wells SA; Freedman RB; Römer RA
    Bioinformatics; 2012 Feb; 28(3):350-7. PubMed ID: 22291339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.